Study to Understand the Safety and Effectiveness of Larotrectinib for Advanced or Recurrent TRK Fusion Cancer in All Ages

What this Trial Is About

Researchers are studying larotrectinib as a treatment for people of all ages with advanced or recurring TRK fusion cancer, a type of cancer caused by a specific gene fusion that leads to cancer cell growth. This research aims to gather real-world information about how larotrectinib affects patients when used as part of their regular medical care. Participants receive larotrectinib prescribed by their doctors according to usual clinical practice. The study does not require extra visits or tests beyond what patients normally have during their treatment. Researchers will collect data from medical records, interviews with patients or their guardians, and regular doctor visits. The study includes various cancer types such as gastrointestinal, head and neck, lung, soft tissue sarcoma, central nervous system, and melanoma. During the study, researchers will monitor patients for up to about 2 years for adults and 8 years for children. They will track treatment-related side effects, their severity, frequency, seriousness, and outcomes, as well as assess how the cancer responds to larotrectinib. Information like neurological exams, growth changes in children, and overall survival will also be collected to better understand the long-term effects and safety of larotrectinib in routine care.

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes